Author: acn

OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a starting point for assessing potential future expansion up to 300MW in total capacity.Addressing Japan’s AI Infrastructure BottleneckThe shift toward modular architecture directly addresses Japan’s growing demand for the expansion of domestic AI capacity on an accelerated timeline. Unlike traditional "brick-and-mortar" builds that can take years to complete, SuperX’s modular approach accelerates deployment by reducing construction timelines significantly. This new pilot project is designed to be purpose-built for next-generation, liquid-cooled GPUs—capabilities often lacking in legacy data centers.Scalable delivery and reliable operationsPursuant to the MOU, the Parties intend to collaborate on the system-level integration of critical infrastructure, including advanced power systems and liquid cooling solutions essential for continuous AI workloads. The framework also contemplates the future integration of renewable energy components, such as solar and wind power, energy storage systems, and grid interconnection, subject to site conditions, commercial viability and regulatory approvals.To facilitate execution, a joint task force is expected to be established to define technical architecture, governance, and near-term milestones. SuperX will lead the provision of the modular system architecture and power system integration.Executive quote“Speed-to-market is the new currency in the AI race,” said Aiko Furukawa, the CEO of SuperX Industries Co. Limited. “This pilot project in Mie Prefecture is intended to demonstrate how we can deploy AI infrastructure with speed. Alongside our partners, we aim to demonstrate that modular scalability is the most viable path to meeting Japan's surging demand for AI.”Looking aheadLooking forward, the Parties intend to use the initial pilot as a reference framework to evaluate broader modular AIDC opportunities across Japan, including scalable pathways for expansion—subject to further feasibility assessments, regulatory approvals, site conditions, and the negotiation and execution of definitive agreements.About Digital Dynamic IncDigital Dynamic Inc. is one of Japan’s fastest-growing AI infrastructure operators, with a rapidly expanding deployment of NVIDIA-based inference GPU resources. In 2026, the company plans to complete AI data centers in Kagoshima Prefecture and Fukushima Prefecture, reinforcing Japan’s next-generation AI computing foundation.About eole Inceole Inc. is a publicly listed company in Japan with a rapidly growing presence in the domestic GPU server market. The company provides investment and business development support for AI data center development projects, playing an active role in advancing Japan’s AI infrastructure ecosystem.About Woodman IncWOODMAN Inc. is a Japanese technology company focusing on eliminating societal waste by transforming underutilized resources, such as surplus electricity and computing power, into new value. They specialize in constructing optimized computing environments for AI and HPC (High-Performance Computing), bridging the gap between energy infrastructure and, previously, blockchain/mining hardware.About SuperX AI Technology Limited (NASDAQ:SUPX)SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sgSafe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

上海, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK，以下簡稱「公司」），一家專注於創新藥研發、臨床開發、制造及商業化的生物制藥公司，今日宣布與陝西麥科奧特醫藥科技股份有限公司（以下簡稱「麥科奧特」）簽署獨家商業化許可協議，獲得MT1013在中國及亞太區（日本除外）的獨家商業化授權。MT1013為全球首創的雙靶點受體激動劑多肽，可同時靶向鈣敏感受體(CaSR)及成骨生長肽(OGP)受體，開發主要用於治療繼發性甲狀旁腺功能亢進症(SHPT)。此次戰略合作將與雲頂新耀現有腎科管線形成協同效應，強化產品佈局，鞏固公司在亞洲腎髒及自身免疫疾病領域的領導地位，並將產品覆蓋從IgA腎病拓展至更廣泛的慢性腎髒病領域。根據協議，雲頂新耀將向麥科奧特支付人民幣2億元首付款，以及最高不超過人民幣10.40億元的潛在監管及商業里程碑付款。中國III期臨床研究正在進行中，相關臨床開發費用將由麥科奧特承擔。MT1013是由麥科奧特自主研發的全球首創雙靶點多肽新藥，2025年獲美國腎髒病學會（ASN）年會「Late-Breaking」收錄。其開創性地融合了「鈣敏感受體（CaSR）+成骨生長肽（OGP）模擬」雙重作用機制，解決了PTH、鈣、磷代謝平衡的問題，這一全新設計使其在治療繼發性甲狀旁腺功能亢進（SHPT）及相關骨代謝疾病時，首次創造性的從源頭上控制病情，且能通過直接激活成骨通路，主動促進骨形成與修複，實現從「間接抑制骨吸收」到「主動促進骨生成」的治療創新升級。臨床研究證實，MT1013在慢性腎病接受維持性血液透析伴繼發性甲狀旁腺功能亢進患者中，起效迅速、效力強且持久，安全性良好，在綜合達標率（iPTH, 血鈣，血磷均達標）、血鈣鈣化指標的控制及心血管獲益前景上均展示出超越現有療法的潛力。目前，MT1013正在中國開展針對該患者群體的III期臨床研究，已入組超50%。SHPT是慢性腎髒病（CKD）患者最常見的嚴重並發症之一。該疾病導致鈣磷代謝紊亂、甲狀旁腺激素升高、骨病變、血管鈣化等一系列病理變化，顯著增加骨折、心血管事件和死亡風險，是影響CKD患者預後的關鍵因素。隨著全球慢性腎髒病患者規模持續擴大，SHPT及其相關治療需求亦不斷增長。數據顯示，全球CKD患者人數已由2019年的9.052億人增至2024年的10.655億人，預計2030年將超12億人，2035年將超15億人；同期全球SHPT患者人數亦持續增長，預計2030年將達約1.899億人，2035年將達約2.217億人，臨床需求亟待滿足。雲頂新耀董事會主席吳以芳表示：「我們非常高興能與麥科奧特達成此次合作。在全球慢性腎髒病患者持續增加的背景下，繼發性甲狀旁腺功能亢進仍存在顯著臨床未滿足需求。MT1013作為具備全球首創雙重作用機制的臨床後期創新資產，有望為SHPT患者提供全新的治療選擇。作為潛在同類最佳藥物，MT1013將與公司現有的腎科產品組合形成高度協同，進一步夯實公司在腎科領域的佈局。雲頂新耀在持續深耕自身免疫相關腎髒疾病的基礎上，正加速拓展至腎小球腎炎以及慢性腎髒病及其並發症等更廣泛的治療領域。此次合作是公司完善創新管線、拓展腎科治療邊界的重要戰略舉措，標志著腎科戰略由聚焦單一疾病領域向系統化和平台化的發展階段升級。未來，雙方將協同推進MT1013的開發與商業化，為更廣泛的腎病患者提供創新治療選擇。」麥科奧特創始人、董事長王冰博士表示：「我們很高興與雲頂新耀達成此次戰略合作。雲頂新耀在腎病領域擁有深厚的市場積累和成熟的商業化體系，是推動MT1013惠及中國乃至全球患者的理想合作夥伴。MT1013是公司多肽技術平台的重要成果，代表著公司在慢病創新治療領域深耕的重要里程碑達成，其獨特的雙靶點機制有望為SHPT治療帶來突破和更多獲益。我們期待與雲頂新耀緊密協作，加速該產品的臨床開發和上市進程，共同滿足廣大未滿足的臨床需求，開啟腎病領域治療的全新篇章。」MT1013已完成關鍵II期臨床研究，數據顯示，MT1013在維持性血液透析伴SHPT患者中，展現出強效且持久的iPTH抑制能力，並在與依特卡肽頭對頭比較中實現了綜合管理的優勢——其iPTH、血鈣、血磷三項同時達標率更高，降磷及降低心血管風險標志物FGF-23的優勢更強，加之MT1013在長達52周的治療中也為患者人群帶來了顯著的骨密度提升及骨代謝標志物改善，逐步驗證了其獨特的雙重機制在SHPT患者中綜合管理及改善骨骼健康方面的潛在臨床獲益。目前MT1013已進入以西那卡塞為陽性對照的確證性III期臨床試驗。該III期試驗已在全國範圍內啟動超過100家研究中心，計劃招募約424名患者，主要針對慢性腎髒病維持性血液透析伴 SHPT的患者群體。關於MT1013MT1013為全球首創的雙靶點受體激動劑多肽，可同時靶向鈣敏感受體（CaSR）及成骨生長肽（OGP）受體，開發主要用於治療繼發性甲狀旁腺功能亢進症（SHPT），並計劃拓展至包括慢性腎病性礦物質和骨代謝異常（CKD-MBD）伴骨質疏松及未接受透析的SHPT在內的額外適應症。MT1013已於2025年5月完成針對SHPT的II期臨床研究（MT1013-II-C01），並已進入以西那卡塞為對照的III期臨床研究。關於雲頂新耀雲頂新耀是一家專注於創新藥研發、臨床開發、制造和商業化的生物制藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先制藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並嚴格按照國家藥品監督管理局（NMPA）和歐洲藥品管理局（EMA）的 GMP 要求及世界衛生組織（WHO）PQ 標准建設。公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎髒及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命周期商業化能力於一體的商業化平台，並以擁有全球權益的自研 mRNA 平台為基礎，持續推進mRNA in vivo CAR-T 與 mRNA 腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。關於麥科奧特陝西麥科奧特醫藥科技股份有限公司（以下簡稱「麥科奧特」）於2007年1月在西安成立，現已完成西安、蘇州、北京、上海、中國香港、美國佈局。公司是一家專注於新藥研發的創新型醫藥科技企業，致力於成為雙功能和多功能特異性多肽藥物研發的領軍性前沿企業，聚焦於心腦血管、代謝類疾病相關領域的新藥研發。公司是是雙特異性多肽概念的提出者、實施者、驗證者和開發者，是多肽類藥物研發的優秀平台之一，具有篩選多靶點多肽藥物的特殊機制，具備開發First-in-class和Best-in-class品種的平台型研發能力，現已儲備多個新藥品種，其中進入臨床研發的有7個原研創新藥管線，包括1個臨床三期階段，3個臨床二期階段，3個臨床一期階段。公司致力於創制新藥、挽救生命，滿足未被滿足的臨床需求，用科技創新為人類健康保駕護航。更多信息，請訪問公司官網：www.micot.cn。前瞻性聲明本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

東京, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 專注於產業用貴金屬展開業務的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（總公司：東京都中央區，執行總裁：田中 浩一朗）發表在接受委託製造包括體外診斷試劑在內之各種檢驗套組的業務中，確立可一次對應所有製程的綜合式的解決方案體制。迄今為止，TANAKA持續負責的主要是從開發和製造檢驗套組到批量製造萃取液，而此次設置分注及包裝萃取液的生產線，並整建了從開發到製成最終產品可一貫在公司內部完成的體制。藉此得以削減外包與運送所耗費的成本和時間，並可在更短期間內提供高品質產品。另外，預計於2026年3月新增導入最新型的自動組裝產線及萃取液分注設備，旨在進一步擴大生產能力和縮短前置時間。TANAKA綜合式的解決方案體制 透過強化一貫生產體制實現彈性應對透過確立此次綜合式的解決方案體制，從開發和製造檢驗套組到批量製造、分注、包裝萃取液的各個製程已可一貫接受委託。藉此，從客戶的開發階段到量產除了能夠持續支援之外，也可應對僅進行藥劑分注等個別製程的委託。透過在自家公司內部完成的生產製程，進而實現進一步強化穩定供應和品質管理。在廣泛疾病領域中檢驗套組的開發實績與推展實例推出了可應對廣泛傳染病的體外診斷試劑，像是包含流感病毒與新型冠狀病毒等在內的呼吸道傳染病，以及登革病毒與茲卡病毒等。這些檢驗套組已可應對像是唾液、血液及尿液等多種檢體，協助醫療現場進行迅速且準確的診斷。呼吸道傳染病病媒蚊傳染病婦產科・流感病毒・腺病毒・人類呼吸道融合病毒・人類間質肺炎病毒・新型冠狀病毒・A群β型溶血性鏈球菌（鏈球菌）・登革病毒・茲卡病毒・屈公病毒・驗孕試劑TANAKA檢驗目標疾病領域的推展實例技術基礎與今後展望TANAKA自約2006年起開始研究開發體外診斷試劑，並持續培育以金（Au）膠體粒子為核心的技術。擁有多項使用免疫層析法以支援試劑提高性能的技術，像是蛋白質固定化技術、非特異性吸附抑制技術，以及抗原抗體反應增強技術等。而在ISO 13485的認證下，亦運用這些技術接受委託製造高品質檢驗套組。今後將會運用這套綜合式的解決方案體制，也會在與合作夥伴企業進行協作的同時，致力於開發新的診斷試劑，為解決社會課題與推動醫療現場的進步作出貢獻。關於TANAKATANAKA自1885年（明治18年）創業以來，營業範圍以貴金屬為中心，並以此展開廣泛活動。在日本國內，以最高水準的貴金屬交易量為傲的TANAKA，長年以來除了進行產業用貴金屬產品的製造和販售外，並提供資產用與珠寶用的貴金屬商品。本集團以貴金屬專業團隊之姿，旗下的國內外各集團公司協調合作，使製造、販售與技術一體化，並供應相關產品與服務。2024 年度（2024年12月止）的合併營業額為8,469億日圓，擁有5,591名員工。產業事業全球網站https://tanaka-preciousmetals.com產品諮詢表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-on-industrial-products/新聞媒體諮詢處TANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-for-media/新聞稿: https://www.acnnewswire.com/docs/files/20260205_CT.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

比利時莫爾塞爾, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 亞格法醫療保健公司今日宣布，其於美國三大企業影像領域榮獲2026年度「最佳KLAS®」殊榮，其中兩項獎項更實現連續兩年蟬聯，彰顯該公司在提供以臨床醫師為核心的影像解決方案方面持續領先，其產品深受全球醫療機構信賴。此項殊榮正值KLAS研究成立三十週年之際，該機構三十年來始終透過獨立、數據驅動的洞察力，為醫療服務提供者發聲。愛格華醫療榮獲Best in KLAS獎項，彰顯其企業影像平台獲得客戶高度認可。該平台旨在賦能臨床醫師保持工作流暢度，簡化影像工作流程複雜性，並透過連通高效的影像與數據存取機制，助力臨床決策信心提升。最佳KLAS®評鑑 - 企業影像解決方案（美國）放射學企業影像解決方案：於PACS（小型系統 - 低於30萬份研究）領域以93.2%評分榮登榜首。XERO® Viewer：連續三年蟬聯通用影像閱片系統（影像類）榜首，評分達92.1%企業影像VNA系統：連續兩年榮登供應商中立檔案庫（VNA）類別榜首，評分達89.8%「在三大企業影像領域獲得認可——包括多次連續獲獎——有力印證了我們以臨床醫師為核心的戰略方針，」愛格華醫療總裁娜塔莉·麥考利表示。「醫療機構信賴我們能打造真正支援臨床醫師日常工作的影像環境，同時讓資訊技術與臨床領導者得以憑藉信心、效能及長遠視野開展工作。這項殊榮彰顯了我們合作夥伴關係的實力，以及我們始終如一地致力於透過互聯智能影像賦能醫療團隊。」針對本次獲獎，KLAS Research執行長亞當·蓋爾評論道：「最佳KLAS獎項得主在過去一年贏得了客戶的信任。這項認可將為未來數月醫療科技與服務領域的合作樹立卓越標竿。」KLAS Research全球影像副總裁莫妮克·拉斯班德補充道：「愛格華醫療在多個企業影像領域的卓越表現，反映出客戶的一致評價。醫療機構深知解決方案的價值——這些方案不僅能協助影像團隊提升當前工作效率，更為未來的成長與創新鋪設清晰路徑。」「最佳KLAS獎項」基於醫療服務提供者的直接反饋，表彰那些透過合作夥伴關係、卓越表現及對客戶需求的敏捷回應，持續展現卓越表現的供應商。AGFA HealthCare將於HIMSS 2026大會期間，攜手客戶與合作夥伴共同慶祝榮獲Best in KLAS殊榮，此舉彰顯該公司持續致力於推動大規模、互聯互通、智能且以人為本的影像解決方案。KLAS參考資料最佳KLAS獎項概覽：《2026最佳KLAS獎項：軟體與服務報告》企業影像分項報告：《2026最佳KLAS獎項：軟體與服務報告》關於亞格法醫療保健在亞格法醫療保健，我們深知要實現臨床效率與優質病患照護之間的關鍵平衡，首要之務在於提升臨床醫師的使用體驗。我們深知臨床醫師全神貫注於病例、傾注全力做出確信且明智診斷的重要性。正因如此，我們設計了企業影像平台以消除干擾因素。當干擾消弭，科技將成為思維的延伸，每位臨床醫師皆能掌握所需資源，發揮專業巔峰水準——這便是「流暢工作」的真諦。此信念貫穿我們所有行動——以使命、願景及客戶交付原則為指引，致力賦能臨床醫師並提升其體驗。亞格法醫療為亞格法集團旗下事業部。欲瞭解更多資訊，請造訪 www.agfahealthcare.com 並於 LinkedIn 追蹤我們。AGFA 及 Agfa 菱形標誌為 Agfa-Gevaert N.V. 比利時公司或其附屬機構之註冊商標。XERO 為 Agfa HealthCare N.V. 比利時公司或其附屬機構之註冊商標。本文所載所有資訊僅供參考之用，本刊所述產品與服務之特性可隨時變更，恕不另行通知。部分產品與服務可能未於您所在地區提供。請洽詢當地銷售代表以確認供應狀況。AGFA HealthCare 致力提供最精確資訊，惟對任何印刷錯誤概不負責。關於 KLAS ResearchKLAS Research 是領先的醫療保健資訊科技數據與洞察公司，致力透過放大醫療服務提供者的聲音來改善全球醫療服務。KLAS 將於 2026 年慶祝成立 30 週年，其透過基於直接客戶反饋的獨立研究評估供應商表現。Best in KLAS® 是 KLAS Research 的註冊商標。新聞聯絡人：Jessica Baldry，愛格法醫療保健全球行銷與傳播經理電話：+44 1206 413052電郵：jessica.baldry@agfa.com 消息來源：愛格法醫療保健 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 4, 2026) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report the additional analytical results of the Company's definition drilling campaign at the 100% owned flagship Trojárová Antimony-Gold Project (the "Project") in Slovakia as announced on November 4, 2025. The 2025 drilling campaign was designed to confirm historical drilling results and to support SLR Consulting's work towards establishing a current mineral resource estimate on the Project, which the company anticipates delivery of by the end of Q1, 2026, further discussed in the Company's January 9, 2025 announcement.These priority assay results represent the main mineralized zone from the third hole of the program, 25-TVA-003.Highlights of the Results from hole 25-TVA-003 Include:23.5 drilled (m) of 3.3 g/t Gold over a true width of 20.2m from 148.9m to 172.4mIncluding: 4.0m of 10.52 g/t Au over a true width of 3.4m from 157.9m to 161.9m1.9m of 2.53% Antimony over a true width of 1.6m from 169.9m to 171.8mScott Eldridge, Chief Executive Officer of the Company, commented, "We are thrilled with the second tranche of assays as we continue to see antimony grades that are consistent with historical results and higher than anticipated gold grades within the Trojárová Deposit. These strong gold results present the Company with new exploration opportunities that we are excited to evaluate. Trojárová represents the only antimony deposit in the European Union being advanced by modern mineral exploration and demonstrates characteristics that place it among the leading antimony projects globally. At a time when the need for secure, domestically sourced critical minerals is more pressing than ever, these results strengthen the project's potential importance to, and alignment with, the EU's objective of building a dependable, home-grown supply of essential raw materials."The Company additionally announces that logging and sampling of all drill core from the program is complete and all samples have successfully been delivered to ALS Laboratories in Roșia Montană, Romania for analysis. Additional results for all holes are pending.Table 1. Complete table of analytical results discussed in this release. Results exceeding 1.0 % Sb or 1.0 g/t Au are highlighted in red.Hole IDFrom (m)To (m)Drilledlength (m)True Width (m)Sample IDAntimony %Gold g/t25-TVA-003145.55146.50.950.813256260.016 0.01 146.5147.10.60.513256270.093 0.04 147.1148.110.863256280.123 0.52 148.1148.90.80.693256290.116 0.38 148.9149.910.863256311.145 1.1220.15m @ 3.3g/t True Width 149.9150.910.863256320.244 0.75 150.9151.910.863256330.057 0.7 151.9152.910.863256340.057 3.74 152.9153.910.863256360.279 4.5 153.9154.910.863256370.031 0.81 154.9155.910.863256380.189 1.05 155.9156.910.863256390.96 1.62 156.9157.910.863256410.807 1.3 157.9158.910.863256420.522 18.653.43m @ 10.52 g/tTrue Width158.9159.910.863256430.098 3.93159.9160.910.863256440.148 13.1160.9161.910.863256450.046 6.38161.9162.910.863256460.091 1.47 162.9163.910.863256470.169 0.76 163.9164.910.863256480.116 4.72 164.9165.910.863256490.088 1.76 165.9166.910.863256510.656 1.31 166.9167.910.863256520.307 1.37 167.9168.910.863256530.107 1.38 168.9169.910.863256540.247 1.19 169.9170.80.90.773256553.641.63m @ 2.53% True Width2.87 170.8171.810.863256561.542.66 171.8172.40.60.513256570.163 1.04 172.4173.410.863256580.136 0.08 173.4174.20.80.693256590.021 0.01 174.21750.80.693256610.582 0.35 17517610.863256621.57 0.71 17617710.863256630.097 2.01 177177.250.250.213256640.034 0.04 177.251780.750.643256660.507 0.34 17817910.863256670.103 0.24 17918010.863256680.261 0.62 18018110.863256690.1 0.54 181181.50.50.433256710.183 0.24 181.5182.510.863256720.018 0.01 182.5183.510.863256730.006 0.01 Figure 1. Gold mineralized drill core from hole 25-TVA-003 - 156.86m - 162.65m. Interval 157.9m to 161.9m yielded a composite grade of 10.52 g/t Au.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_002full.jpgFigure 2. Map of 2025 and Soviet era diamond drillholes in the north-central portion of Military Metals Trojárová Project.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_003full.jpgTable 2. Drillhole collar information for the Company's 2025 diamond drilling campaign at Trojárová. Locations presented are final and determined by a professional and qualified surveyor. WGS 84 / UTM Zone 33N DrillholeEastingNorthingElevation (m)Length (m)DipAzimuth25-TVA-0016626965358601640292.2-6522025-TVA-0026626855358668655289.7-7522025-TVA-0036625515358701634200.2-6522525-TVA-0046624755358809604256.5-5522525-TVA-0056623945358812580196-6023025-TVA-006662211535879556962.4-5722025-TVA-007662170535885255986.5-60210 Analytical and QA/QC ProceduresThe program was completed using PQ and HQ sized drill core. Sampled intervals were identified by logging geologists and assigned a unique sample identification number. Samples were split in two halves using a diamond bladed saw with one half remaining in the core box as a permanent record and the half placed in a plastic sample bag, both marked with a waterproof tag bearing the unique sample number which was also written on the sample bag in permanent marker. Samples were transported from the Company's secure facility by private courier to ALS Laboratories in Romania for geochemical analysis. ALS Laboratories is an independent ISO/IEC 17025:2017 and ISO 9001:2015 certified commercial laboratory with no relationship to the Company. The samples were analyzed using multi-element package ME_ICP41a and for gold using fire assay package Au-AA25. ME_ICP41a is an ore grade package involving digestion of a 0.4g sample by aqua regia with an Inductively coupled plasma - atomic emission spectrometry (ICP-AES) finish. The Au-AA25 fire assay method is an ore grade analysis using a 30g aliquot. The aliquot is mixed with flux composed of PbO and SiO2 with variable amounts of borax, soda ash and other reagents. The flux and sample are mixed, then heated at high temperature (>1,000°C) to decompose rock lattices and allow gold within the sample to be collected into a lead button. The button is placed in a porous cupel and heated again in an oxidizing environment to convert lead to lead oxide that is absorbed into the cupel, leaving the precious metals behind as a doré bead or prill. The gold content of the prill is then determined by atomic adsorption spectrometry.Both analyses are preceded by the preparation package Prep-31Y whereby the entire sample is crushed to 70% passing 2mm, a 250g split is collected by rotary splitter and pulverized to 85% passing 75 microns. Laboratory over-limits analysis methods were applied as required for both Sb and Au. A systematic QAQC protocol was employed that includes systematic insertion in the sample stream of certified reference materials and blank samples at a frequency of 1 in 10, plus analysis of duplicate pulp splits at a frequency of 1 in 30.About the Project and Historical ResourceDiscovered in the late 1970s, Trojárová was the focus of extensive surface and underground exploration over a 2km strike length from 1983 to 1995, with 63 core holes for a total of 14,330m, and 1.7km of underground workings completed. Efforts continued over the years as additional trenches were dug, and holes were drilled. Starting in 1990, underground development work began ultimately comprising a 300-meter-long adit connected to a 700-plus meter-long drive in the footwall of the mineralized zone with seven crosscuts into the mineralized zone for sampling purposes.These efforts culminated in a comprehensive study comprising drill logs, analyses, drill plans, maps and sections, deposit model studies, petrographic studies, metallurgical studies and more, now detailed in a multi-volume compendium of reports produced by the Slovak Geological Institute published in 1992, including a historical mineral resource estimate (see "Historical Resource Estimates" below). Per this historical estimate, at a cut-off grade of 1.0% antimony, Trojárová hosts 2.46 million tonnes averaging 2.47% antimony and 0.635 grams per tonne gold in a mineralized zone averaging 3.32 meters wide, containing approximately 60,000 tonnes of antimony in situ.Historical Resource EstimatesThe historical estimate related to the Trojárová Property was taken from a compendium produced by the Slovak Geological Survey, completed in March 1992 based on exploration work undertaking in the 1980s and 1990s. It is entitled (English translation): "FINAL JOB REPORT, PEZINOK-TROJAROVA, Geological Survey State Enterprise", report compendium number 78406 (Michel et al, 1992).The Slovak Geological Institute, the state agency that carried out all exploration and underground development work at Trojárová, classified the historical resources as "P1" and "C2" in the Slovak version of the Russian classification system, respectively. These are closest within the Canadian Institute of Mining, Metallurgy & Petroleum's ("CIM") classification system to "inferred mineral resources," which is defined by the CIM as that part of a mineral resource for which quantity and grade or quality are estimated on the basis of limited geological evidence gathered through appropriate sampling techniques from locations such as outcrops, trenches, pits, workings and drill holes.The historical work carried out appears comprehensive, detailed and at a professional standard. The Company considers this historical data to be relevant as the Company will use these data as a guide to plan future exploration programs. The Company also considers the data to be reliable for these purposes. A qualified person has not done sufficient work to classify the historical estimate as current, and the Company is not treating the historical estimate as current.Qualified PersonThe technical contents of this release were reviewed and approved by David Murray, P.Geo, VP-Exploration for Military Metals and a qualified person as defined by National Instrument 43-101.For more information about Military Metals Corp. and its critical minerals initiatives, please visit: https://www.militarymetalscorp.com.LinkedIn: https://www.linkedin.com/company/military-metals/X: https://x.com/militarymetalsFacebook: https://www.facebook.com/profile.php?id=61564717587797About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.com or info@militarymetalscorp.comFor enquiries, please call 604-537-7556Forward-Looking StatementsThis news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes the timing of the mineral resource estimate being currently conducted, and its completion at all, future drilling and exploration work at Trojárová, the continuation of the value of antimony, and the future needs of Europe and the E.U. specifically. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include geopolitical developments related to the supply and value of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the property that is the subject of this news release, the results of any future exploration activities, which cannot be guaranteed, and any other future activities in respect of the property held by the Target. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282604 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRUSSELS, BELGIUM, Feb 4, 2026 - (ACN Newswire via SeaPRwire.com) - Airwheel recently announced the continued rollout of its AI-driven rideable smart cabin suitcase solutions, marking a new phase in the evolution of intelligent travel mobility as global demand for smart transportation accelerates. Today, Airwheel’s sales and distribution network spans 68 countries and more than 4,600 retail locations worldwide. As its global expansion continues, the company’s electric and smart suitcases are transitioning from innovative products into high-frequency travel tools used by consumers around the world.Looking ahead, Airwheel will continue to advance the evolution of rideable smart luggage across technology, user experience, and application scenarios, allowing intelligent systems to integrate into travel in a more natural and intuitive way—so that travel becomes not just a means of transportation, but an opportunity to explore the world and enjoy life.As smart mobility continues to reshape global travel and transportation, intellectual property and design capability have emerged as key factors distinguishing true industry leaders from short-term innovators. In the field of rideable suitcase and smart mobility solutions, Airwheel has steadily strengthened its leadership position through long-term, systematic investment in technology and design.As one of the pioneers of the rideable smart luggage category, Airwheel has built a clear and robust competitive moat at the core technology level. To date, the company has accumulated more than 600 patents worldwide, covering critical areas such as motion control algorithms, electric drive systems, intelligent sensing, and structural design, including multiple international invention patents. In parallel, Airwheel has advanced its global intellectual property strategy, with trademarks registered in more than 168 countries and regions, providing a solid foundation for regulatory compliance, large-scale commercialization, and long-term brand development across international markets.Amid the rapid iteration of smart mobility products, design capability has become an equally important measure of product maturity. If patents represent technological depth and engineering strength, then international design awards serve as authoritative recognition of product philosophy, user experience, and comprehensive design excellence. In recent years, multiple Airwheel smart products have received recognition from leading global design awards, including the German iF Design Award, the U.S. IDEA Awards, the IAI Design Award, and the Berlin Design Award, demonstrating the brand’s consistent and high-level design output in the smart mobility space.These awards go far beyond aesthetics, evaluating products across dimensions such as usability logic, safety architecture, engineering integrity, human–machine interaction, and future application potential. Recognition from such professional juries indicates that Airwheel’s smart suitcase designs have been rigorously validated for both functional completeness and real-world usability, further enhancing the brand’s credibility in global markets.At the product level, the global popularity of the Airwheel SE3S Series marks a significant milestone in bringing rideable smart luggage into the mainstream. True product maturity is not defined solely by technical completeness, but by its ability to enter popular culture and everyday consumer awareness. Driven by social media and short-form video platforms, the Airwheel SE3S Series has become a favored electric suitcase among international celebrities, content creators, and fashion-forward travelers—often described as both a mobility tool and a “mobile lifestyle accessory.”Frequently seen in airports, fashion events, street photography, and travel scenarios, this rideable smart cabin suitcase not only serves a functional purpose but also delivers emotional value and personal expression. According to public data and platform analytics, content related to the Airwheel SE3S Series has generated tens of billions of impressions globally, transcending the boundaries of a single product category and becoming widely recognized as a fashionable travel symbol in the digital era.User feedback has further reinforced this dual identity. Many consumers describe the SE3S Series as “instantly recognizable” and “a travel companion that makes journeys lighter and more enjoyable,” strengthening its positioning at the intersection of smart mobility and lifestyle consumption.Notably, Airwheel has expanded its smart luggage ecosystem beyond adult users. The company also offers the SQ3 Series, a rideable smart suitcase designed specifically for children. By prioritizing safety and structural stability, the SQ3 Series introduces greater interaction and enjoyment into family travel, positioning smart luggage as an integral part of the parent-child travel experience.From a compliance perspective, the Airwheel SE3S Series is designed as a cabin suitcase, featuring a detachable lithium battery that meets airline safety standards, allowing it to be carried onboard flights in accordance with major international airline regulations. This design enables frequent, legal, and reliable use in airport environments worldwide, making it a practical choice for international travelers.Evolving from a mobility device into a source of emotional value and, ultimately, a widely recognized fashion travel product, the rise of the Airwheel SE3S Series signals that rideable smart luggage is becoming a natural part of everyday global travel.About AirwheelFounded in 2004, Airwheel is a global smart transportation device manufacturer with R&D, marketing, manufacturing, and logistics centers in the United States, Belgium, and China. The company has integrated the portable transportation industrial chain and built a globally recognized brand, serving more than 30 million users across 68 countries. Guided by its philosophy of “Free Intelligent Life,” Airwheel leverages technologies such as IoT sensors, robotics, and deep learning to develop intelligent mobility solutions that enhance freedom, joy, and everyday travel experiences worldwide.Media ContactCompany: AirwheelContact: Media TeamWebsite: https://www.airwheel.net Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ROMEOVILLE, IL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup.With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (< 30 days), and other non-implantable applications requiring strength, clarity, chemical resistance, and consistent processing.Key medical grade materials include:VESTAMID® Care ML PA12VESTAMID® Care ME PEBA elastomerTROGAMID® Care MX microcrystalline PA"Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions," said Steve Harmon, Director, Key Accounts, Formerra. "Evonik's healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices.""Formerra's ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step," said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. "Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications."By adding Evonik's healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra's team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.Key Details:Formerra will distribute Evonik's CARE brand healthcare grades across the U.S. and Canada.Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.The agreement strengthens Formerra's medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About EvonikEvonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. To learn more, visit www.evonik.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月4日 - (亞太商訊 via SeaPRwire.com) - 1月29日，由華泰保險經紀與上海國際再保險登記交易中心聯合承辦的菲律賓頭部能源集團Aboitiz Power全球統保項目中國市場保險排分風險路演會，在上海臨港國際再保險登記交易中心成功舉辦。作為Aboitiz Power 2026年度全球四地（上海、倫敦、新加坡、迪拜）路演的首站，是該集團首次登陸中國市場開展全球統保項目路演，也是上海國際再保險登記交易中心開業以來舉辦規模最大的國際保險業務路演，此次活動不僅彰顯了其對中國市場的高度認可，更印證了中國保險市場的承保實力、服務水平及華泰經紀的專業能力，為深化高水平對外開放、賦能全球能源合作注入強勁動力。上海自由貿易試驗區臨港新片區管理委員會金融貿易處處長殷軍，Aboitiz Power集團首席戰略官兼首席風險官史蒂夫‧邦茲，華泰保險經紀董事長杜奎峰，上海國際再保險登記交易中心總經理趙雷，以及20餘家保險公司、再保險公司的100餘位專家代表出席本次路演，共同探討為全球能源項目及綠色轉型提供風險保障的「中國方案」。鏈接全球，首啟中菲能源保險新征程作為Aboitiz Power全球統保路演的中國首秀，此次臨港活動搭建起中菲能源保險合作的橋樑，成為兩國深化能源領域協同、對接全球保險資源的重要起點。 上海自由貿易試驗區臨港新片區管理委員會金融貿易處處長殷軍表示，上海臨港正全力打造全球領先的國際再保交易市場，主動服務國家高水平對外開放戰略大局，並就支持產業發展的相關優惠政策進行全面解讀，同時還介紹了政策的具體落實情況。此次路演既是對中國保險市場、上海國際再保險登記交易中心及華泰經紀專業能力的認可和肯定，更是推動中國國際保險市場高質量發展、提升跨境金融服務能力的重要契機。Aboitiz Power集團首席企業服務官表示，中國與菲律賓有著諸多相似的發展境遇，本次交流將是阿博伊蒂斯能源與中國保險業界深化合作、攜手同行的起點。Aboitiz Power集團首席戰略官兼首席風險官史蒂夫‧邦茲介紹，作為菲律賓領先的能源企業，Aboitiz Power集團擁有百餘年的運營歷史，是菲律賓領先能源企業，發電量佔該國電力需求超20%，公司整體戰略佈局正積極深化與中國市場的全方位合作，是中國領軍能源建設和設備供應企業的重要合作夥伴。此次將整體保險業務向中國市場排分，包括由中國企業承建和設備供應的新能源建設項目，上海路演是集團全球佈局的重要一環。深耕佈局，共築全球能源風險保障網依託臨港新片區的制度優勢與行業資源，上海國際再保險登記交易中心、華泰經紀與各方力量協同發力，立足專業優勢深耕佈局，助力搭建全球能源項目風險保障體系，為能源合作築牢安全屏障。華泰經紀董事長杜奎峰表示，華泰經紀始終以服務共建「一帶一路」為使命，國際化與創新是公司「十五五」規劃的核心戰略。立足中國企業高質量「走出去」新階段，華泰經紀願與行業同仁攜手，通過產融深度融合，從服務中國出海企業與產品起步，延伸至賦能其全球上下游生態夥伴，助力中國實體產業提升海外綜合競爭力，構建互利共贏海外利益共同體。上海國際再保險登記交易中心總經理趙雷表示，中心將致力於打造高效標準、透明規範的新型再保險交易體系，推動我國保險業高質量發展、深化全球風險治理合作。當前，中國在國際保險市場佔有率仍有較大提升空間，鼓勵行業各方積極參與國際競爭與合作，把握這一推動中國保險市場實現新增長、開拓新格局的重要機遇。攜手共進，賦能「一帶一路」高質量發展此次路演凝聚行業共識、整合優質資源，推動各方在全球能源風險保障領域達成深度協作，為「一帶一路」能源合作注入保險力量，助力實現高質量發展。路演環節，Aboitiz Power與華泰經紀的專家先後介紹了項目排分情況、實施計劃及承保條件，中國太保、平安、人保、中再產險等機構圍繞項目風險保障、合作模式、跨境服務等核心問題開展深度交流，凝聚廣泛共識，為後續合作落地奠定堅實基礎。此前華泰經紀已成功協助Aboitiz Power在中國市場排分多個項目，此次路演旨在整合直保與再保資源，構建全球能源風險保障合力，探索「一帶一路」生態夥伴海外風險協同保障機制，打造可複製的風險管理範式。當前，「十五五」規劃開局起步，中國企業高質量「走出去」步伐持續加速，國家戰略的內涵與外延不斷豐富。未來，華泰經紀將持續以自身為核心，深耕國際化佈局，攜手行業同仁，以產融結合為紐帶，在構建「中資利益—中國元素—中國影響力」多層輻射圈的海外產業生態中，持續提升中國保險產業的國際話語權，推動跨境保險合作深化，為共建「一帶一路」高質量發展、促進中菲能源深度合作貢獻華泰力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 3, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa"), is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement (the "Offering"). The Company has closed on a total of 4,917,000 units (each, a "Unit") at a price of $0.125 per unit for gross proceeds of up to $614,625.00.Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (each full warrant, a "Warrant"). Each of the 4,917,000 Warrants entitles the holder to acquire one additional share for a period of two years until February 04, 2028. The warrant exercise strike price is $0.15/share in the first three months and automatically converts to $0.20 per share then after for the remainder of the two years period.All issued Securities will be subject to a 4-month and one day hold-period, during which any resale or other transfer will be restricted in accordance with applicable securities laws.A Finder's Fees of $24,000 has been paid to registered financial institutions.Net proceeds from the offering will be used for general administration, exploration and development activities on the Company's projects in Arizona, and British Columbia, Canada. The Company will continue to raise the remaining placement in the coming week.The completion of the private placement remains subject to approval of the TSX Venture Exchange.None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.About Casa Minerals Inc.The Company is engaged in the acquisition, exploration and development of mineral properties located in Canada and the USA. Casa owns ninety percent (90%) interest in the Congress gold mine (Arizona, USA). Additionally, the Company owns a one hundred percent (100%) interest in the polymetallic Pitman (BC, Canada) and has an option to acquire a seventy-five percent (75%) interest in the Arsenault VMS Property (BC, Canada).On Behalf of Board of Directors,Farshad Shirvani, M.Sc. GeologyPresident and CEOFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comhttps://www.casaminerals.comNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282620 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今天公佈消費者展望調查結果，顯示大多數亞洲中產階級對財務狀況感到焦慮，且對退休準備不足。隨着生活成本不斷上升及家庭責任增加，各世代的財務優先次序正被重新塑造。近四分三（71%）受訪的中產消費者對整體財務狀況感到壓力，三大主要憂慮包括：生活成本上升（71%）、高昂醫療費用（43%）以及擔心意外失業或收入減少（37%）。因此，他們的首要財務目標聚焦於兩至三年內的短期規劃。近半數（44%）受訪者旨在為家庭建立基本保障，而三分一（37%）則期望達致財務獨立。富衛集團分銷兼產品主張及策劃總監Lee Yen Ho表示：「顯然，亞洲各世代中產階層普遍存在財務脆弱感。隨著人口壽命延長與家庭結構演變，建立財務韌性以守護所愛，並將儲蓄轉化為可持續的終身收入，將變得日益重要。創造保險新體驗因而發揮關鍵作用。保險不僅能在困難時期提供保障，更有助建構抗風險能力、確保退休收入，讓所有人能自信地盡興人生。」調查亦揭示了明顯的跨代壓力：- X世代（出生於1965至1980年）面臨最艱難的平衡考驗：需同時負擔教育開支、償還房貸及準備退休。當中有62%擔心儲蓄無法抵禦通脹，52%將保障終身收入列為退休首要需求。- Y世代（出生於1981至1995年）同時肩負多重財務責任，其中49%擔心自己的退休儲蓄不足。大部分（85%）除養育子女外，還需供養父母。儘管近半數（47%）希望尋找單一高效的保險以保障多名家庭成員，但大多數（61%）從未聽聞相關的家庭保障計劃。- Z世代（出生於1996至2010年）財務壓力日增，53%預期未來五至十年會因日常開支上升而面對困難，另有46%認為保險產品價格過高。是次泛亞調查與市場研究公司益普索合作，訪問了逾9,000名年齡介乎於21至65歲的中產消費者，涵蓋富衛營運的十個市場：柬埔寨、香港特別行政區、印尼、日本、澳門特別行政區、馬來西亞、菲律賓、新加坡、泰國及越南。富衛在其市場提供多元產品，旨在加強保障、提升財務韌性及建立長期的財務安全。例如在香港推出「人仁保醫療保險計劃」提供靈活的家庭保障及設有免健康核保的添加自選保障。在日本，為了滿足日益增長的儲蓄和退休規劃需求，富衛推出了一款日圓整付保費年金產品，幫助個人和家庭建立穩定的退休收入來源。於泰國及新加坡推出的「FWD Sure Pension 」計劃及「FWD Invest Flexi Elite 」計劃協助客戶透過結構化收入及可持續的財富增長選項做好退休準備。於印尼，「FWD Critical First」保障計劃提供可負擔及對抗通脹的保障，協助家庭在生活成本上漲的環境下保障財務健康。關於富衛集團富衛集團（香港聯合交易所上市代號：1828）為泛亞洲人壽及健康保險公司，服務約3,400萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團在香港聯合交易所有限公司主板上市，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings Limited Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

伊利諾州羅密歐維爾市, 2026年2月2日 - (亞太商訊 via SeaPRwire.com) - 高性能材料分銷領導企業福美拉今日宣布擴大分銷協議，將埃文斯CARE品牌醫療級產品納入其醫療產品組合。此涵蓋美國與加拿大的協議，為關鍵醫療應用領域的高性能聚醯胺材料開創全新通路。此擴展合作將於本週舉行的MD&M West 2026展會啟動，彰顯雙方以高性能材料、即時服務及穩定供應支持醫療市場的承諾。此舉亦延續兩家公司兩年的合作基礎——此前已將埃文斯VESTAMID®與TROGAMID®系列納入Formerra工程材料產品線。透過此次擴展，Formerra將支援艾維尼專為以下應用設計的醫療級產品：流體處理、藥物輸送、診斷系統、手術器械零件、醫療設備外殼、短期體內接觸部件（

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 全球最大釣魚裝備製造商樂欣戶外（股票代碼2720.HK）正式啟動招股，擬全球發售2820.5萬股，其中10%為香港公開發售。每股定價12.25港元。預計2月10日在聯交所掛牌上市。此次IPO擬集資約3.45億港元，中金公司擔任獨家保薦人。市場地位穩固，龍頭份額持續提升根據弗若斯特沙利文的權威數據，全球釣魚用具市場規模預計將於2029年達到1941億元，其中全球釣魚裝備市場展現出更快的增長勢頭，2025年至2029年的複合年增長率預計為9.5%，明顯高於行業整體。樂欣戶外作為全球最大的釣魚裝備製造商，市場份額為23.1%，同時在前五大廠商中佔據絕對主導地位。樂欣戶外亦是中國最大的釣魚裝備製造商，市場份額由2022年的23.4%穩步增長至2024年的28.4%，展現出持續增長潛力。中國釣魚裝備製造業也更為集中，按2024年收入計前五大釣魚裝備製造商所佔市場份額為39.4%。業績穩健增長，產品線覆蓋全面在財務數據層面，樂欣戶外營收保持高速穩健增長，2024年營收達5.73億元，較2023年實現23.8%的同比增長；2025年前八個月收入已達4.60億元，接近2024年全年的80%，顯示增長節奏穩健。公司2025年前八個月實現經營利潤7769.5萬元，接近2022年歷史較好水平，為公司戰略擴張提供了堅實的資本基礎。2025年前八個月淨利潤達5624.1萬元，淨利潤率維持在12.2%的健康水平，為公司戰略擴張提供了堅實的資本基礎。其中品牌業務增長迅猛，自有品牌Solar 2024年銷售額較2018年增長近三倍，儘管目前OBM業務佔比並不是很髙，但增長潛力巨大。同時，公司TO B業務持續發力，合作超過5年的客戶達84家，客戶黏性強勁，形成「TO B穩健托底+TO C突破增長」的雙增長格局，為長期資本回報提供穩定支撐。在產品矩陣層面，樂欣戶外為不同釣魚場景創造出了全面的產品解決方案。截至2025年8月31日的產品組合涵蓋10,000多個SKU，可適配釣魚人在不同地區及環境的需求，包括鯉魚釣、比賽釣、路亞釣、飛釣及冰釣等。市場前景廣闊，加碼品牌與未來 從全球格局來看，釣魚裝備市場正迎來結構性增長機遇。專業機構研究顯示，2025至2029年，全球釣魚裝備市場預計將以年均約9.5%的複合增速擴張，高於戶外行業整體水平，市場總規模有望邁向2000億元。我國垂釣裝備行業已邁入藍海發展階段，行業紅利為樂欣戶外的轉型提供了廣闊空間。機構數據顯示，2020-2024年，我國垂釣裝備行業市場規模年均複合增長率達18.92%，顯著高於全球同期水平，全球市場佔比持續提升，市場需求正從基礎功能滿足向專業化、場景化及個性化升級。此次IPO募資是樂欣戶外發展歷程中的重要里程碑，亦是其在資本層面提升核心競爭力、拓展戰略布局的關鍵舉措。伴隨全球休閒釣魚生活方式的熱潮，消費者對高品質釣魚裝備的需求持續攀升，新興市場的增速尤為顯著。作為全球規模最大的釣魚裝備製造商，樂欣戶外可依託自身產能與產品優勢，充分承接這一藍海市場的需求紅利，為品牌升級與市場拓展築牢基礎，迎來全新的發展機遇。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 近日，由上海實業（集團）有限公司（以下簡稱“上實集團”）與Azzurra Capital聯合發起設立的亞洲環境科技合夥企業（Asia Environmental Technology Fund，簡稱“AETF”），已成功完成首關。AETF同步密集召開系列重要會議、深化多方合作對接，穩步推進落地運營與儲備項目佈局。作為上實集團與Azzurra Capital聯手打造的專業綠色投資平台，AETF擬定目標規模為5億美元。AETF將立足香港、面向全球，錨定綠色發展時代機遇，滙聚亞歐及中東優質資本支持，致力於成為跨境環境科技投資領域的標杆力量。依託「歐洲技術引進+亞洲企業出海」的雙向跨境賦能模式，AETF將國際私募股權的專業投研能力與上實集團深厚的產業資源深度融合，緊扣全球ESG主題尤其是環境科技投資目標，充分借助亞洲工業基礎與政策紅利，精選具備高增長潛力的投資標的。通過雙向賦能策略，既加速歐洲前沿環境技術在亞洲的場景落地，也助力亞洲綠色龍頭企業邁向全球，兼顧成熟項目的穩健回報與早期科技項目的成長潛力，助力亞洲穩步邁向「碳達峰、碳中和」綠色未來。AETF將重點涵蓋可再生能源產業鏈、能源轉化和儲能技術、賦能綠色低碳發展的數智化技術（AI、IoT及智能製造）、循環經濟與資源再生、可持續農業與未來食品體系、氣候科技（CCUS）及環境監測解決方案、具備全球出口競爭力的綠色消費品與可持續生活方式等領域。1月27日，AETF的GP公司召開首屆董事會，凝聚合作共識、明晰推進路徑、建立合規體系、儲備重點項目、細化落實舉措。在董事會召開期間，AETF董事和高管團隊圍繞落地運營、投資策略優化、多方合作拓展等召開了一系列專題會議，並同步拜訪了香港多家知名機構，圍繞環境健康領域潛在投資機遇、合作模式創新、跨境金融合規建設、項目協同聯動、優質資源分享等議題深入交流討論，為AETF精準對接香港本地優質資源、拓寬跨境合作版圖築牢根基。上實集團與Azzurra Capital將憑藉各自獨特優勢，構建起優勢互補、協同發展的良好合作格局。上實集團自1981年在香港成立以來，聚焦生命健康與環境健康兩大核心賽道，在產業整合、項目運營、本地資源對接等方面積累了深厚底蘊與豐富經驗。Azzurra Capital作為擁有成熟跨境基金管理經驗的知名投資機構，資產管理規模近9億美元，在歐洲、中東等地擁有廣泛的優質資源與優秀的投資業績，深耕綠色科技與可持續發展領域，專業能力獲行業認可。雙方攜手發起設立AETF，既是響應全球低碳轉型號召、踐行綠色發展理念的重要舉措，也是深化跨境投資合作、支援滬港協同發展，賦能亞洲環境科技產業高質量發展的具體實踐，更是雙方實現優勢互補、合作共贏的戰略抉擇。香港當前正在全力發展創科、綠色金融等新引擎，通過扮演更積極的「超級聯繫人」和「超級增值人」角色，在服務國家大局中實現自身的高質量發展。作為上實集團在港開展金融投資業務的平台，上實資本（香港）本次與Azzurra Capital合作攜手發起設立AETF，是上實資本（香港）緊抓當前香港發展機遇，服務在港發展，充分激發「香港所長」與「上海所能」的互補勢能，系統推動兩地創新鏈、產業鏈、資金鏈與人才鏈的深度融合的具體實踐，將為加快構建開放融合、連結全球的創新生態系統，為滬港國際科技創新中心建設提供支撐。上實集團首席金融投資官谷峰先生表示，此次與Azzurra Capital的合作，是上實集團將深厚產業資源與全球資本及頂尖投資管理經驗深度融合的重要戰略舉措。期待通過AETF這一平台，不僅投資技術，更致力於培育產業。我們將積極開放自身的應用場景與生態系統，為優秀的綠色科技企業提供從驗證到規模化發展的全方位支援，共同推動亞太區域的綠色轉型與高質量發展。Azzurra Capital創始合夥人Stefano Eugenio Marsaglia指出，亞洲作為全球低碳轉型的核心陣地，擁有巨大的投資潛力與廣闊的發展空間，綠色發展已成為不可逆轉的時代潮流。AETF的成功設立，搭建起了連接歐洲、中東與亞洲綠色投資市場的重要橋樑，未來將充分發揮雙方專業優勢，推動先進技術、優質資本與廣闊市場的跨境流動，全力打造亞洲環境科技投資領域的標杆，為全球低碳轉型貢獻力量。風勁潮湧正當時，揚帆奮進啟新程。AETF將以此次首關為重要契機，加速推進後續擴募進程，聚焦核心投資領域精準發力、推進優質項目落地見效，持續深化與各方機構的合作對接，積極開展品牌建設與行業交流。AETF將始終以「歐洲技術引進+亞洲企業出海」雙向策略為核心，持續作為雙方跨境綠色合作的核心載體，在各類行業峰會中傳遞合作價值、連結優質資源。AETF將以資本為紐帶、以創新為動力，賦能亞洲環境科技產業高質量發展，推動ESG投資理念深度落地，為全球低碳轉型注入持久動能、貢獻堅實力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com